Cyclerion Therapeutics (NASDAQ:CYCN) Issues Quarterly Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) issued its quarterly earnings results on Tuesday. The company reported $0.22 earnings per share (EPS) for the quarter, Zacks reports.

Cyclerion Therapeutics Price Performance

Shares of Cyclerion Therapeutics stock traded up $0.23 during trading on Tuesday, hitting $2.63. 42,403 shares of the stock were exchanged, compared to its average volume of 2,872,864. The firm’s 50-day moving average price is $3.18 and its 200 day moving average price is $2.92. Cyclerion Therapeutics has a 12-month low of $1.27 and a 12-month high of $9.47.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.